2/26
06:07 am
halo
Halozyme Therapeutics (HALO) was downgraded by
Weiss Ratings from "buy (b-)" to "hold (c)".
Low
Report
Halozyme Therapeutics (HALO) was downgraded by
Weiss Ratings from "buy (b-)" to "hold (c)".
2/25
08:56 am
halo
Halozyme to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Halozyme to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/25
08:47 am
halo
2 Reasons to Like HALO (and 1 Not So Much) [Yahoo! Finance]
Low
Report
2 Reasons to Like HALO (and 1 Not So Much) [Yahoo! Finance]
2/25
08:30 am
halo
Halozyme to Participate in Upcoming Investor Conferences
Low
Report
Halozyme to Participate in Upcoming Investor Conferences
2/19
07:05 pm
halo
Why Halozyme Therapeutics (HALO) Is Down 7.9% After Acquisition-Driven Q4 Loss And 2026 Outlook Reaffirmation [Yahoo! Finance]
Low
Report
Why Halozyme Therapeutics (HALO) Is Down 7.9% After Acquisition-Driven Q4 Loss And 2026 Outlook Reaffirmation [Yahoo! Finance]
2/19
02:28 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Benchmark Co. from $75.00 to $90.00. They now have a "buy" rating on the stock.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Benchmark Co. from $75.00 to $90.00. They now have a "buy" rating on the stock.
2/19
09:44 am
halo
Halozyme (HALO) Loses 9% on Weak Earnings [Yahoo! Finance]
Low
Report
Halozyme (HALO) Loses 9% on Weak Earnings [Yahoo! Finance]
2/19
09:34 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Wells Fargo & Company from $65.00 to $75.00. They now have an "equal weight" rating on the stock.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Wells Fargo & Company from $65.00 to $75.00. They now have an "equal weight" rating on the stock.
2/18
12:05 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at TD Cowen.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at TD Cowen.
2/18
12:12 am
halo
Halozyme Therapeutics Inc (HALO) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Medium
Report
Halozyme Therapeutics Inc (HALO) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
2/17
08:29 pm
halo
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/17
08:29 pm
halo
Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline [Seeking Alpha]
Medium
Report
Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline [Seeking Alpha]
2/17
07:56 pm
halo
Halozyme Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Halozyme Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/17
06:15 pm
halo
Halozyme (HALO) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Halozyme (HALO) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/17
04:39 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales [Yahoo! Finance]
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales [Yahoo! Finance]
2/17
04:30 pm
halo
Halozyme Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Halozyme Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
2/17
04:01 pm
halo
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
Low
Report
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
2/15
08:01 am
halo
The biopharma company trying to simplify drug delivery for patients [Yahoo! Finance Canada]
Low
Report
The biopharma company trying to simplify drug delivery for patients [Yahoo! Finance Canada]
2/11
06:32 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
2/10
04:33 pm
halo
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results [Yahoo! Finance]
Low
Report
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results [Yahoo! Finance]
2/10
04:05 pm
halo
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
Low
Report
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
2/10
11:26 am
halo
Biotech: Halozyme CEO explains what it looks for in M&A targets [Yahoo! Finance]
Low
Report
Biotech: Halozyme CEO explains what it looks for in M&A targets [Yahoo! Finance]
2/10
11:16 am
halo
Biotech: Halozyme CEO explains what it looks for in M&A targets [Yahoo! Finance Canada]
Low
Report
Biotech: Halozyme CEO explains what it looks for in M&A targets [Yahoo! Finance Canada]
2/6
10:36 am
halo
A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance [Yahoo! Finance]
Low
Report
A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance [Yahoo! Finance]
2/3
12:01 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..